Market Intelligence, Clinical Progress, and High-Purity Reagents for Cell Cycle Regulation & Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDKN2C drug discovery and CDK4/6 pathway validation. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDKN2C Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for biophysical binding assays. |
View CDKN2C Products |
| Gene Delivery | CDKN2C Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View CDKN2C Products |
| Benchmark Ab | Anti-CDKN2C Recombinant Antibody High-specificity positive control for IHC, Western Blot, and IP validation. |
View CDKN2C Products |
| Validator | CDKN2C siRNA Set For knockdown verification in functional cell-cycle arrest assays. |
View CDKN2C Products |
| Related Target A | CDK4 Primary interaction partner of CDKN2C; critical for direct binding and competitive inhibition assays. |
View CDK4 Products |
| Related Target B | CDK6 Synergistic cell cycle kinase; crucial for specificity and selectivity screening. |
View CDK6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Assessing CDKN2C-CDK4/6 binding disruption | Sequence-verified recombinant CDKN2C and CDK4/6 proteins with high purity (>95%) for robust SPR/BLI assays. |
| Intracellular pathway validation | Lentivirus premade particles for stable over-expression to bypass transient transfection limitations. |
| Lack of Controls | Sequence-defined Recombinant Benchmark Antibodies included for reproducible assay baselines. |
| False Positives in Knockdown | Sequence-optimized and validated siRNA pools included for high-specificity target knockdown. |
Live CDKN2C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the cyclin-dependent kinase inhibitor 2C (CDKN2C, p18-INK4C) pathway is rapidly evolving. As a critical tumor suppressor that inhibits CDK4 and CDK6, loss of CDKN2C is a well-established driver of accelerated cell proliferation in multiple myeloma, breast cancer, and medulloblastoma. Rather than directly targeting the mutated or deleted tumor suppressor, the therapeutic landscape focuses on restoring CDKN2C-like inhibition using small-molecule CDK4/6 inhibitors or developing PROTACs that target downstream cell-cycle machinery. The next wave of R&D is heavily directed toward overcoming acquired resistance to CDK4/6 inhibitors, where CDKN2C status serves as a key biomarker for patient stratification and combination therapy design.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (CDK4/6i) | Pfizer, Eli Lilly, Novartis | HR+/HER2- Breast Cancer, Liposarcoma | Selectivity Assay (Need High-Purity Mutant & WT CDK4/6 and CDKN2C) |
| Gene Therapy / mRNA | Academic Institutes, Biotech Startups | Multiple Myeloma, Glioblastoma | Overexpression Validation (Need High-Titer Lentivirus) |
| PROTAC / Degraders | Arvinas, Kymera Therapeutics | Refractory Solid Tumors | Ternary Complex Formation Assay (Need Tagged Recombinant Proteins) |